Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemigliptin in Diabetic Nephropathy
NCT04705506Completed
- Sponsor
- Vajira Hospital
- Start
- Feb 2017
- Primary completion
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of gemigliptin in diabetic nephropathy (DN), sponsored by Vajira Hospital. Primary endpoint: Markers of renal injury at 6 months. Started Feb 2017; status: completed.
02
Drugs
gemigliptin
03
Conditions
diabetic nephropathy (DN)
Beyond the preview
Go deeper on NCT04705506.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04705506.